RS20220433A1 - Multitarget antiviral dietary supplement - Google Patents
Multitarget antiviral dietary supplementInfo
- Publication number
- RS20220433A1 RS20220433A1 RS20220433A RSP20220433A RS20220433A1 RS 20220433 A1 RS20220433 A1 RS 20220433A1 RS 20220433 A RS20220433 A RS 20220433A RS P20220433 A RSP20220433 A RS P20220433A RS 20220433 A1 RS20220433 A1 RS 20220433A1
- Authority
- RS
- Serbia
- Prior art keywords
- substance
- virus
- multitarget
- antiviral
- hcov
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title abstract 4
- 235000015872 dietary supplement Nutrition 0.000 title abstract 4
- 239000000126 substance Substances 0.000 abstract 8
- 241000700605 Viruses Species 0.000 abstract 5
- 230000009385 viral infection Effects 0.000 abstract 4
- 229940096437 Protein S Drugs 0.000 abstract 3
- 101710198474 Spike protein Proteins 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 239000004615 ingredient Substances 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- 101800000504 3C-like protease Proteins 0.000 abstract 1
- 101800000535 3C-like proteinase Proteins 0.000 abstract 1
- 101800002396 3C-like proteinase nsp5 Proteins 0.000 abstract 1
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 abstract 1
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 abstract 1
- 241001678559 COVID-19 virus Species 0.000 abstract 1
- 102100031673 Corneodesmosin Human genes 0.000 abstract 1
- 208000001490 Dengue Diseases 0.000 abstract 1
- 206010012310 Dengue fever Diseases 0.000 abstract 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 abstract 1
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 abstract 1
- 241000711467 Human coronavirus 229E Species 0.000 abstract 1
- 241001109669 Human coronavirus HKU1 Species 0.000 abstract 1
- 241000482741 Human coronavirus NL63 Species 0.000 abstract 1
- 241001428935 Human coronavirus OC43 Species 0.000 abstract 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 abstract 1
- -1 PLpro Proteins 0.000 abstract 1
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 abstract 1
- 241000315672 SARS coronavirus Species 0.000 abstract 1
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 abstract 1
- 108010031318 Vitronectin Proteins 0.000 abstract 1
- 208000025729 dengue disease Diseases 0.000 abstract 1
- 235000021112 essential micronutrients Nutrition 0.000 abstract 1
- 230000020764 fibrinolysis Effects 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 206010022000 influenza Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 230000029812 viral genome replication Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention provides a multitarget antiviral dietary supplement, that can comprise the following ingredients: at least one virus spike protein (e.g., an S-protein) binding substance, at least one virus spike protein receptor (e.g., an ACE2 receptor) binding substance, at least one substance for preventing virus from entering cells (e.g., a TMPRSS2 inhibitor), and at least one substance for preventing virus replication in cells (e.g., inhibitors 3CLpro/Mpro, PLpro, RdRp, etc.). The multitarget antiviral dietary supplement may additionally contain: at least one substance for increasing the bioavailability of other substances, at least one essential micronutrient, at least one substance for fibrinolysis against thrombs, as well as at least one substance for treatment, after which the complete product might become a drug in some countries. The multitarget antiviral dietary supplement can be used for: virus infection prevention, home (outpatient) treatment of virus infection, hospital (inpatient) treatment of virus infection, post-recovery after virus infection, minimization of drugs side effects and minimization of vaccine side effects, wherein viruses can be: SARS-CoV-2, SARS-CoV, MERS, Influenza, HIV-1, HCoV-229E, HCoV-NL63, HCoV-OC43, HCoV-HKU1, hepatitis, Dengue fever, West Nile, Zika, Nipah, ebola, Marburg, and many others, wherein naturally selected ingredients can be optimized for individual viruses.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RS20220433A RS20220433A1 (en) | 2022-05-11 | 2022-05-11 | Multitarget antiviral dietary supplement |
| PCT/RS2023/050001 WO2023219526A1 (en) | 2022-05-11 | 2023-05-11 | Multitarget antiviral dietary supplement |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RS20220433A RS20220433A1 (en) | 2022-05-11 | 2022-05-11 | Multitarget antiviral dietary supplement |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS20220433A1 true RS20220433A1 (en) | 2023-11-30 |
Family
ID=87036826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20220433A RS20220433A1 (en) | 2022-05-11 | 2022-05-11 | Multitarget antiviral dietary supplement |
Country Status (2)
| Country | Link |
|---|---|
| RS (1) | RS20220433A1 (en) |
| WO (1) | WO2023219526A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024112947A1 (en) * | 2022-11-23 | 2024-05-30 | Brightseed, Inc. | Compositions and methods for modulating sleep and uses thereof |
| WO2024113024A1 (en) * | 2022-12-02 | 2024-06-06 | MUCPharm Pty Ltd | Compositions and methods for treating fungal infections |
| CN117959284A (en) * | 2023-12-28 | 2024-05-03 | 华南农业大学 | Application of andrographolide in preparing anti-rabies medicine |
| CN118593536A (en) * | 2024-06-17 | 2024-09-06 | 威海人生药业集团股份有限公司 | Traditional Chinese medicine composition for preventing and treating arteriosclerosis and coronary heart disease |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6887497B2 (en) | 2002-12-19 | 2005-05-03 | Vitacost.Com, Inc. | Composition for the treatment and prevention of osteoarthritis, rheumatoid arthritis and improved joint function |
| US20150056176A1 (en) | 2012-01-18 | 2015-02-26 | Stanley N. Jankowitz | Anti-inflammatory composition |
| EP3347009B1 (en) * | 2015-07-08 | 2021-10-13 | Triple Hair Inc. | Composition comprising resveratrol and melatonin for reducing hair loss and/or increasing hair regrowth |
| IT201600128994A1 (en) | 2016-12-20 | 2018-06-20 | Inpha Duemila Srl | Formulations for use in the treatment of endometriosis and associated disorders |
| IT201700088621A1 (en) | 2017-08-01 | 2019-02-01 | Inpha Duemila Srl | Food supplements for use in the treatment of diseases associated with alterations of peripheral nerve trophism. |
| US10980791B1 (en) | 2018-01-26 | 2021-04-20 | Gene S. Rosen | Multi-component nutritional supplement formulations and treatment regimen |
| GB201811312D0 (en) | 2018-07-10 | 2018-08-29 | Nuchido Ltd | Compositions |
| BR112022014114A2 (en) | 2020-01-17 | 2022-09-13 | Sami Sabinsa Group Ltd | COMPOSITIONS TO MANAGE CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
| EP4121041A4 (en) * | 2020-03-18 | 2024-04-03 | GMP Biotechnology Limited | Tgf-beta inhibition, agents and composition therefor |
| US20210315250A1 (en) | 2020-04-08 | 2021-10-14 | Mark Edward Fenzl | Combination broad-spectrum antiviral natural extract supplements |
| US10987329B1 (en) | 2020-04-22 | 2021-04-27 | Nadimpally Satyavarahala Raju | Combination therapy for coronavirus infections including the novel corona virus (COVID-19) |
-
2022
- 2022-05-11 RS RS20220433A patent/RS20220433A1/en unknown
-
2023
- 2023-05-11 WO PCT/RS2023/050001 patent/WO2023219526A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023219526A1 (en) | 2023-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS20220433A1 (en) | Multitarget antiviral dietary supplement | |
| Guillin et al. | Selenium, selenoproteins and viral infection | |
| Colunga Biancatelli et al. | Quercetin and vitamin C: an experimental, synergistic therapy for the prevention and treatment of SARS-CoV-2 related disease (COVID-19) | |
| Checconi et al. | Redox-modulating agents in the treatment of viral infections | |
| Koutsakos et al. | Downregulation of MHC class I expression by influenza A and B viruses | |
| Andreou et al. | COVID-19: The potential role of copper and N-acetylcysteine (NAC) in a combination of candidate antiviral treatments against SARS-CoV-2 | |
| Haslberger et al. | Mechanisms of selected functional foods against viral infections with a view on COVID-19: Mini review | |
| Zhang et al. | Potential interventions for novel coronavirus in China: A systematic review | |
| Khomich et al. | Redox biology of respiratory viral infections | |
| García-Pérez et al. | Taming the Autophagy as a Strategy for Treating COVID-19 | |
| Mounce et al. | Inhibition of polyamine biosynthesis is a broad-spectrum strategy against RNA viruses | |
| Sohag et al. | Revisiting potential druggable targets against SARS‐CoV‐2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review | |
| Fraternale et al. | Intracellular redox-modulated pathways as targets for effective approaches in the treatment of viral infection | |
| Stancioiu et al. | A dissection of SARS‑CoV2 with clinical implications | |
| Sun et al. | Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19 | |
| Tomo et al. | Selenium to selenoproteins–role in COVID-19 | |
| Naghipour et al. | Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine–from HIV-1 infection to COVID-19 | |
| Ağagündüz et al. | Emergent drug and nutrition interactions in COVID-19: a comprehensive narrative review | |
| Hijikata et al. | Evaluating cepharanthine analogues as natural drugs against SARS‐CoV‐2 | |
| Mast et al. | Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality | |
| Altulea et al. | What makes (hydroxy) chloroquine ineffective against COVID-19: insights from cell biology | |
| Fakhri et al. | Targeting multiple signal transduction pathways of SARS-CoV-2: Approaches to COVID-19 therapeutic candidates | |
| Bellanti et al. | Redox homeostasis and immune alterations in coronavirus disease-19 | |
| Omer et al. | A review on the antiviral activity of functional foods against COVID-19 and viral respiratory tract infections | |
| Raghavan | Metadichol®: A Novel Nanolipid Formulation That Inhibits SARS‐CoV‐2 and a Multitude of Pathological Viruses In Vitro |